Additional file 3 of Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer

Additional file 3 (Fig. S3 Panobinostat exhibits anti-tumors effects in in vivo models of RR-HNC. a Representative tumor images, and b tumor growth curve of WT and RR HK-1 during treatment for 34 days with vehicle control or 2.5 mg/kg Pano. Data presented as mean ± SD, n ≥ 5. *, P < 0.05. c Growth rate of WT and RR HK-1 tumors vehicle control and treated tumors at treatment end-point. Data presented as mean ± SD, n ≥ 5. *, P < 0.05; **, P < 0.01. d Immunohistochemistry (IHC) analysis for Ki67 proliferation marker and TUNEL assay for apoptosis detection in WT and RR HK-1 tumors. Data presented as mean ± SD, n ≥ 5. *, P < 0.05; **, P < 0.01; ***, P < 0.001. e mRNA expression of HDAC6 after Pano treatment in WT and RR FaDu, WT and RR HK-1 tumors. Fold-change is calculated against the respective WT control. Data presented as mean ± SD, n ≥ 5. *, P < 0.05; **, P < 0.01.)